82 filings
Page 2 of 5
8-K
qfwc2ws98ovw dzg
15 Dec 22
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
4:31pm
8-K
4ct4j
10 Nov 22
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
7:15am
8-K
x30jvgx5zvm9 qd1
20 Oct 22
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
8:00am
8-K
edm0lk szy
19 Sep 22
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
8:33am
8-K
caz170m
18 Aug 22
Material Modifications to Rights of Security Holders
6:03pm
8-K
9thos3h3ema0ic8
12 Aug 22
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
7:15am
8-K
bls8ks g58xuw
28 Jul 22
Other Events
5:01pm
8-K
jj01ao
11 Jul 22
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
8:01am
8-K
11yprgh0pvxn8e06l8o
8 Jul 22
Share Option Cancellation Agreement
5:00pm
8-K
lhg kfkj7
16 Jun 22
Submission of Matters to a Vote of Security Holders
8:15am
8-K
d6bdt2z6x4djk9
13 May 22
Iterum Therapeutics Reports First Quarter 2022 Financial Results
7:16am
8-K
rqxhrbhmz
28 Mar 22
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:15am
8-K
wvsivvah15w8d6q
12 Nov 21
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
7:30am
8-K
kxkuy7muzcu
10 Sep 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:17pm
8-K
i03v6bmvdhuvttmcx
13 Aug 21
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
7:15am
8-K
hzbi3bfbl10ncb4rg4
26 Jul 21
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
4:05pm
8-K
huzifeh
2 Jul 21
Iterum Therapeutics Provides Regulatory Update
7:00am
8-K
ysty8f
23 Jun 21
Departure of Directors or Certain Officers
4:01pm
8-K
ys3 n4b50jib5174a2x
14 Jun 21
Departure of Directors or Certain Officers
4:40pm
8-K
aa9jwqdkx
27 May 21
Iterum Therapeutics Provides Update on NDA Review
5:15pm